- Home
- FMY vs RNXT Comparison
FMY vs RNXT Comparison
Compare FMY & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- RNXT
- Stock Information
- Founded
- FMY 2005
- RNXT 2012
- Country
- FMY United States
- RNXT United States
- Employees
- FMY N/A
- RNXT N/A
- Industry
- FMY Finance/Investors Services
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- FMY Finance
- RNXT Health Care
- Exchange
- FMY Nasdaq
- RNXT Nasdaq
- Market Cap
- FMY 50.5M
- RNXT 44.6M
- IPO Year
- FMY N/A
- RNXT 2021
- Fundamental
- Price
- FMY $12.24
- RNXT $1.30
- Analyst Decision
- FMY
- RNXT Strong Buy
- Analyst Count
- FMY 0
- RNXT 2
- Target Price
- FMY N/A
- RNXT $7.25
- AVG Volume (30 Days)
- FMY 10.1K
- RNXT 145.6K
- Earning Date
- FMY 01-01-0001
- RNXT 08-12-2025
- Dividend Yield
- FMY 6.98%
- RNXT N/A
- EPS Growth
- FMY N/A
- RNXT N/A
- EPS
- FMY N/A
- RNXT N/A
- Revenue
- FMY N/A
- RNXT $240,000.00
- Revenue This Year
- FMY N/A
- RNXT $3,186.05
- Revenue Next Year
- FMY N/A
- RNXT $291.93
- P/E Ratio
- FMY N/A
- RNXT N/A
- Revenue Growth
- FMY N/A
- RNXT N/A
- 52 Week Low
- FMY $10.71
- RNXT $0.75
- 52 Week High
- FMY $12.17
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- FMY 67.54
- RNXT 49.27
- Support Level
- FMY $12.08
- RNXT $1.27
- Resistance Level
- FMY $12.05
- RNXT $1.42
- Average True Range (ATR)
- FMY 0.07
- RNXT 0.06
- MACD
- FMY 0.03
- RNXT -0.02
- Stochastic Oscillator
- FMY 94.44
- RNXT 25.00
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.